Covid-19 Vaccine: Aurobindo Expects Phase-I, II Trials By End Of 2020
Aurobindo Pharma has said it is expecting its proposed vaccine candidate for Covid-19 to undergo phase-1 and 2 trials by the end of 2020, while Phase III may be undertaken during March-April next year.
Managing Director Narayanan Govindarajan in the recently held earnings call with analysts said the city-based pharma major had earmarked $150-200 million towards capital expenditure during the current fiscal year.
He said the vaccine for Covid-19 was being developed by Profectus BioSciences in the US, which was acquired by Aurobindo Pharma’s subsidiary Auro Vaccines LLC.
According to Govindarajan, the company's viral vaccine manufacturing capacity in India would be undertaken in two phases.
JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private Equity And Banks: The Complex Web Of Leverage
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
Financial Watchdog Highlights Unresolved Vulnerabilities In Shadow Banking Sector
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more
JPMorgan And Small Caps Lead Market Rally: A Sign Of Economic Optimism
In a week marked by strong financial performance, JPMorgan Chase & Co. reported a 25% rise in profits, and US small-... Read more
Big Banks Vs. Regional Banks: The Battle For Market Share
The financial industry is a competitive landscape where big banks and regional banks vie for market share. Each type of ... Read more
The Evolution Of Philanthropic Advisory Services In Private Banks
The landscape of philanthropic advisory services provided by private banks has undergone a significant transformation. T... Read more